Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

821
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
821
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.4K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

679
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
679
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.3K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

671
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
671

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Based on Hospital Admission Type.

Cutis·2025
Same author

Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study.

Journal of the American Academy of Dermatology·2025
Same author

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.

Journal of cutaneous medicine and surgery·2025
Same author

Implementation of the atopic dermatitis yardstick via the electronic medical record: a pilot study to improve clinical documentation and patient education.

Dermatology online journal·2024
Same author

Outcomes in an educational skin-model session on point-of-care ultrasound for diagnosing calciphylaxis.

Skin health and disease·2024
Same author

Mycophenolate mofetil as a steroid-sparing agent in oral mucous membrane pemphigoid: A retrospective review.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Related Experiment Video

Updated: Oct 13, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

The evolving atopic dermatitis management landscape.

Vikram N Sahni1, Esther A Balogh2, Lindsay C Strowd2

  • 1Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.

Expert Opinion on Pharmacotherapy
|November 11, 2021
PubMed
Summary

New treatments like dupilumab and crisaborole are revolutionizing atopic dermatitis (AD) management. Future therapies, including JAK inhibitors and antibody treatments, offer promising options for patients with AD.

Keywords:
AAD guidelinesAtopic dermatitisJAK inhibitorcrisaboroledupilumabeczemaomalizumabpharmacotherapytreatmentupdate

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

957

Related Experiment Videos

Last Updated: Oct 13, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

957

Area of Science:

  • Dermatology
  • Pharmacology
  • Immunology

Background:

  • Atopic dermatitis (AD) is a prevalent global skin condition.
  • The American Academy of Dermatology (AAD) provided treatment guidelines in 2013-14.
  • Recent FDA-approved therapies have significantly advanced AD management.

Purpose of the Study:

  • To provide a comprehensive review of established and emerging pharmacologic treatments for atopic dermatitis.
  • To update clinicians on the latest efficacy and safety data for AD therapies.
  • To highlight the evolving landscape of AD management.

Main Methods:

  • Review of efficacy and safety data for established AD treatments.
  • Exploration of trial data for newer agents like dupilumab and crisaborole.
  • Examination of studies on emerging therapies including JAK inhibitors and monoclonal antibodies.

Main Results:

  • Established treatments like topical corticosteroids and calcineurin inhibitors remain important.
  • Newer agents such as dupilumab and crisaborole demonstrate significant efficacy.
  • Investigational therapies including JAK inhibitors and anti-IL-13/31 antibodies show promising results.

Conclusions:

  • Current AAD guidelines require updates to incorporate novel AD treatment modalities.
  • Dupilumab and crisaborole have revolutionized AD pharmacologic management.
  • Future therapies like JAK inhibitors and Il-13/31 antibodies hold significant promise for improving patient outcomes.